Conor Stewart
Research expert covering health & pharmaceuticals in the UK & Europe
Get in touch with us now| Characteristic | 2017 | 2024* |
|---|---|---|
| In vitro diagnostics (IVD) | 13% | 13.4% |
| Cardiology | 11.6% | 12.2% |
| Diagnostic imaging | 9.8% | 8.6% |
| Orthopedics | 9% | 7.9% |
| Ophthalmics | 6.8% | 7.1% |
| General & plastic surgery | 5.5% | 5.8% |
| Endoscopy | 4.6% | 4.8% |
| Drug delivery | 4.6% | 4.3% |
| Dental | 3.4% | 3.6% |
| Diabetic care | 2.9% | 3.3% |
| Wound management | 3.2% | 3% |
| Healthcare IT | 2.9% | 3% |
| Neurology | 2.1% | 2.7% |
| Nephrology | 2.9% | 2.6% |
| Ear, nose & throat (ENT) | 2.2% | 2.2% |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Source
Release date
September 2018
More information
Region
Worldwide
Survey time period
as of September 2018
Supplementary notes
Figures are based on the top 300 medtech companies. Sales in 2017 based on company reported data. Sales forecasts to 2024 based on a consensus of leading equity analysts’ estimates for segmental sales.
* Forecast.
Citation formats
